Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Inclusion Criteria:

* Male or female patients 18 years or older.
* Newly Diagnosed non-GCB subtype of DLBCL (Stage II, III or IV).
* At least 1 measurable site of disease.
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Female subjects must be postmenopausal (for at least 6 months), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control before entry and throughout the study; and have a negative pregnancy test at screening.
* Male subjects must agree to use a double barrier method of birth control

Exclusion Criteria:

* Prior treatment with VELCADE.
* Prior extended radiotherapy or chemotherapy for lymphoma
* More than 150 mg/m2 of prior doxorubicin
* Major surgery within 3 weeks of study.
* Peripheral neuropathy or neuralgia of Grade 2 or worse.
* Active CNS lymphoma
* Diagnosed or treated for a malignancy other than NHL, with some exceptions
* Pregnant or breast feeding
* Active systemic infection
* Documented of suspected human immunodeficiency virus (HIV)/AIDS
* Uncontrolled or severe cardiovascular disease
* Known allergies, hypersensitivity or intolerance to study drugs
* Serious medical condition that could interfere with study
* Concurrent treatment with another investigational agent